

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

NCI-H441

RRID:CVCL_1561

Type: Cell Line

Proper Citation

RRID:CVCL_1561

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1561

Proper Citation: RRID:CVCL_1561

Description: Cell line NCI-H441 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung papillary adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:2386953](#), [PMID:3940644](#), [PMID:8806092](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:18083107](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24135919](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H441

Synonyms: H441, H-441, NCI-H441-4, NCI-441, NCIH441

Cross References: BTO:BTO_0001910, CLO:CLO_0008087, EFO:EFO_0002292, AddexBio:C0016019/4975, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783,

ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRM-HTB-174, ATCC:HTB-174, BCRC:60455, BCRJ:0359, BioGRID_ORCS_Cell_line:524, BioSample:SAMN03473121, BioSample:SAMN10988237, cancercellines:CVCL_1561, CCRID:4201HUM-CCTCC00308, CCTCC:GDC0308, Cell_Model_Passport:SIDM00925, ChEMBL-Cells:ChEMBL3308121, ChEMBL-Targets:ChEMBL1075542, CLS:305219, Cosmic:687824, Cosmic:722048, Cosmic:801590, Cosmic:844831, Cosmic:876144, Cosmic:897730, Cosmic:903574, Cosmic:908460, Cosmic:914949, Cosmic:917992, Cosmic:1006533, Cosmic:1028948, Cosmic:1052332, Cosmic:1146916, Cosmic:1219076, Cosmic:1239882, Cosmic:1802306, Cosmic:1870274, Cosmic:1945871, Cosmic:1995577, Cosmic:2042863, Cosmic:2125252, Cosmic:2668311, Cosmic-CLP:908460, DepMap:ACH-000638, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10742-110C4, GDSC:908460, GEO:GSM108851, GEO:GSM108852, GEO:GSM206492, GEO:GSM253415, GEO:GSM274741, GEO:GSM274742, GEO:GSM353231, GEO:GSM385521, GEO:GSM385532, GEO:GSM434308, GEO:GSM784265, GEO:GSM794287, GEO:GSM817073, GEO:GSM827516, GEO:GSM844650, GEO:GSM887428, GEO:GSM888508, GEO:GSM1670243, IARC_TP53:518, IARC_TP53:21408, IGRhCellID:NCIH441, IZSLER:BS TCL 215, LiGeA:CCLE_935, LINCS_LDP:LCL-1911, PharmacDB:NCIH441_1112_2019, PRIDE:PXD002556, PRIDE:PXD005187, PRIDE:PXD030304, Progenetix:CVCL_1561, PubChem_Cell_line:CVCL_1561, Wikidata:Q54908052

ID: CVCL_1561

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181245+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H441.

No alerts have been found for NCI-H441.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 302 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE?? with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. Journal of medicinal chemistry.

Suzuki S, et al. (2026) Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. *Cancer immunology research*, 14(7), 1172.

Mi W, et al. (2026) LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. *Cell reports*, 45(6), 117487.

Shao H, et al. (2026) KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. *Science advances*, 12(8), eaea2511.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. *Science translational medicine*, 18(840), eadx4097.

Li C, et al. (2025) Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 ?? PD-L1 Antibody-Drug Conjugate. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3581.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Sagie S, et al. (2025) Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation. *Cell reports. Medicine*, 6(12), 102506.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.

Kramer-Drauberg M, et al. (2025) Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. *Molecular oncology*, 19(2), 311.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular cell*, 85(7), 1311.

Ray P, et al. (2025) SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy. *Molecular cancer research : MCR*, 23(6), 530.

Wang W, et al. (2025) Genome-Wide CRISPR Screen Reveals PIK3CA Inhibition Enhances Lipid Nanoparticle-Mediated siRNA Delivery. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e17617.

Enokido T, et al. (2024) Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma. *Molecular cancer research : MCR*, 22(1), 29.

Wang M, et al. (2024) Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates. *Cell chemical biology*, 31(12), 2039.